tbuckley/cabot-search huggingface dataset:
AB1297 EVALUATION OF POSSIBLE RISK FACTOR OF PULMONARY EMBOLISM IN SARCOIDOSIS PATIENTS
Authors: B. Ruaro, P. Confalonieri, C. Torregiani, S. Pichierri, M. Confalonieri, F. Salton
Journal: Annals of the Rheumatic Diseases (2022)

Background Some studies reported a correlation between sarcoidosis and an increased risk of pulmonary embolism (PE) 1,2 . Objectives To assess possible risk factors of PE in sarcoidosis patients. Methods We enrolled 260 sarcoidosis patients (170 females and 90 males; mean age at diagnosis 46 ± 9), after giving written informed consent. We perform clinical evaluations, laboratory tests and radiology features. Results Our study population included 20 sarcoidosis patients with PE (14 females and 6 males; mean age at diagnosis 45 ± 10), diagnosed by lung scintigraphy and 240 sarcoidosis patients without PE (170 females and 70 males; mean age at diagnosis 46 ± 11). There was a significant increase of the presence of antiphospholipid antibodies in the sarcoidosis group with pulmonary embolism (55%) than in group without PE (9%) (p-value&lt;0.01). There was no statistically significant difference between the two groups on smoking habit, obesity, treatments and hereditary thrombophilia frequency (p &gt; 0.05, respectively). Conclusion This study demonstrated an increased of antiphospholipid antibodies positivity in sarcoidosis patients with pulmonary embolism. Furthermore, we propose screening for these antibodies in all sarcoidosis patients. References [1]Turetz M, et al. Semin Intervent Radiol 2018;35:92–98 [2]Larsson J, et al. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37: 104-135 Disclosure of Interests None declared
POS1541-HPR PAIN CATASTROPHIZING IS FREQUENT AND IMPACTS THE LIFE AND FUNCTION OF PATIENTS WITH SPONDYLOARTHRITIS
Authors: A. Ben Tekaya, C. Ines, A. Gharbi, O. Saidane, R. Leila, S. Bouden, R. Tekaya, I. Mahmoud, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2022)

Background Psychological care for patients with spondyloarthritis (SpA) should be standard practice if we aim to achieve better outcomes. In fact, pain catastrophizing, anxiety, and depression are to look for when the patient remains unsatisfied despite the clinicobiological control of the disease. Objectives To assess the presence of pain catastrophizing among patients with SpA. Methods We conducted a cross-sectional study including patients with SpA, fulfilling the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria. For all patients, we collected the socio-demographic data and disease characteristics, the following scores: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath ankylosing spondylitis functional index (BASFI), the Ankylosing spondylitis quality of life score (ASQOL) were used to evaluate respectively disease activity, functional status and quality of life. The presence of pain catastrophizing was assessed by the arabic validated version of Pain catastrophizing score (PCS) and nociplastic pain by Central Sensitization Inventory (CSI). Results We included 60 SpA patients (sex ratio=1,72). Mean age was 39,4 years ± 11,08. Mean disease duration was 11,37 years ±7,23. Mean BASDAI score was 3,53± 3,34, mean BASFI was 4,01 ±2,53 and mean ASQOL score was 6,3 ±5,12. Mean PCS was 15,73 ± 13,893. thirteen patients (21,7%) had PCS &gt;30 which indicates clinically relevant level of catastrophizing. PCS was significantly higher in men (mean PCS was 19,29 in men versus 9,59 in females), p=0,003. Clinically relevant level of catastrophizing (PCS&gt;30) was significantly associated with age: mean age was 45,61 years in patients with PCS&gt;30 compared to 37,47 in patients with lower PCS (p=0,022). Higher PCS was correlated with greater central sensitization assessed by the CSI (p&lt;0,0001, r=0,621), poorer quality of life assessed by the ASQOL (p&lt;0,0001, r=0,818) and greater functional impairment appraised by BASFI (p=0,009, r=0,347). No correlation was shown between PCS and age (p=0,640, r=0,062), age at disease onset (p=0,580, r=-0,84), disease duration (p=0,805, r=0,037), patient’s global assessment (p=0,211, r=0,197), CRP value (p= 0,425, r=-0,130) and BASDAI score (p=0,073, r=0,244). Conclusion Pain catastrophizing was not influenced by inflammation parameters. PCS was correlated with greater central sensitization, poorer quality of life and greater functional impairment. Therefore, psycho-education should be investigated among patients with SpA. Disclosure of Interests None declared
AB1374 INTERSTITIAL LUNG DISEASE IN ASYMPTOMATIC PATIENTS AT THE ONSET OF INFLAMMATORY RHEUMATIC DISEASES
Authors: T. Hoffmann, P. Oelzner, F. Marcus, M. Förster, U. Teichgräber, G. Wolf, A. Pfeil
Journal: Annals of the Rheumatic Diseases (2022)

Background Interstitial lung disease (ILD) in inflammatory rheumatic diseases (IRD) is associated with increased mortality. Moreover, the lung is one of the most effected organs on IRD, but the clinical manifestations and severity can vary from subclinical abnormality to dyspnoea, respiratory failure, and death. Objectives The objective of the following study is to evaluate the frequency and type of ILD in asymptomatic patients at the onset of IRD. Methods The study represents a sub-analysis of a case-control study performed earlier, and includes 126 patients with a newly diagnosed IRD. The study cohort was divided in two groups (ILD group: n = 63 and control group: n = 63). The patients were evaluated for respiratory symptoms (cough, sputum, dyspnea) and sclerosiphonia. If possible, all patients received a lung function test and optional a chest x-ray. Patients with pathological findings in the screening tests (chest x-ray or reduced diffusing capacity for carbon monoxide (DLCO) &lt; 80 %) maintained a high-resolution computer tomography (HR-CT) of the lung. The sub-analysis includes 20 patients with asymptomatic ILD at the onset of IRD. Results The asymptomatic ILD group consists out of 75 % female (n = 15) and 25 % male (n = 5) patients, with median age of 51.8 years (SD ± 17.1 years). In comparison, asymptomatic ILD patients are significant younger (t(27.4) = 2.36, p = 0.026), but the distribution of gender is similar. The mean values in different pulmonary function parameter are: FVC: 89.9% ± 19.3%; DLCO: 69.9% ± 21.2%; FEV1: 87.9% ± 21.4%; TLC: 91.0% ± 16.5% and TLCO: 82.1% ± 20.6% (FVC = Forced Vital Capacity, FEV1 = Forced Expiratory Volume in 1 second, TLC = Total Lung Capacity, TLCO = Transfer factor of the Lung for carbon monoxide). The observed CT patterns are pure ground glass opacities (GGO) (50%, n = 10), non-specific interstitial pneumonia (NSIP) (25%, n = 5), granuloma/proliferations (15%, n = 3), usual interstitial pneumonia (UIP) (5%, n = 1) and lymphocytic interstitial pneumonia (LIP) (5%, n = 1). The distribution of CT pattern was not significant to the symptomatic ILD group (χ 2 (6) = 10.224, p = 0.116). Conclusion The study highlighted that also clinical asymptomatic patients have ILD in IRD at the onset of the IRD. Frequently, a reduced DLCO is detectable in PFT as a sign of early lung involvement, so this represents a potential screening parameter. Moreover, asymptomatic patients are often younger than symptomatic patients. No significant difference was found in CT pattern, but further research is needed as the number of patients is quite small. Disclosure of Interests None declared
POS1188 INCIDENCE AND MANIFESTATIONS OF LYME DISEASE: A SINGLE-CENTER RETROSPECTIVE ANALYSIS.
Authors: S. Pūce, A. Pūce, A. Mihailova
Journal: Annals of the Rheumatic Diseases (2022)

Background Lyme disease is widespread throughout the world, including Latvia. On average period 2009 to 2018, there have been 613 cases of Lyme disease registered in Latvia every year according to data from the Center for Disease Prevention and Control. Mainly early skin manifestations such as erythema migrans and neurological manifestations such as meningitis, cranial neuropathy and motor or sensor radiculoneuropathy of this disease are being discussed and emphasized. Therefore, undiagnosed and unexamined often remain articular manifestations of Lyme disease, leading to prolonged treatment and reduced patient quality of life. Objectives To investigate clinical presentation, immunological changes, and response to therapy in patients with Lyme disease. Methods A retrospective single center study was performed in the outpatient clinic Orto (Riga, Latvia) in the period from January 2018 until December 2021. Medical records from patients with diagnosed Lyme disease and articular symptoms, based on epidemiological, clinical and immunological findings, were analyzed. Patients who had other types of arthropathies were excluded. Results In total 76 patients were included in the study (54 females, 22 males, age range 19-84 years, median age 48.5 years), of whom 48 patients had arthritis and 28 arthralgias. Out of all patients with arthritis - 25 had monoarthritis, 16 - had oligoarthritis and 7 had polyarthritis. At the first visit patients with arthralgia had a median IgM 28.2 Au/ml (IQR 15.27- 47.35) and IgG 25.00 Au/ml (IQR 5.00 – 142.30) and patients with arthritis had a median IgM 14.7 Au/ml (IQR 5.50 - 28.80) and IgG 142.7 Au/ml (IQR 82.32-237). After the treatment with Doxycycline 200 mg QD for 30 days, 52 patients came to the 2nd visit, of them 41 patients with improvement of symptoms and 11 without. More improvement was seen in the arthritis group. After treatment the median IgM in arthralgia/ arthritis groups was 22.5 Au/ml (IQR 8.72-38.82) / 13.8 Au/ml (IQR 6.03-24.15) and IgG was 42.4 Au/ml (IQR 8.15 – 90.60) / 106.7 Au/ml (IQR 23.57-203.95). In both groups with arthralgias or arthritis, patients who had a positive clinical response after treatment had a significantly lower post-treatment IgG than before treatment (p &lt;0.05, Wilcoxson signed rank test). At the same time patients who did not respond to the treatment had no significant difference between pre- and post- treatment IgG antibodies (p&gt; 0.05, Wilcoxson signed rank test). Conclusion In all patients with musculoskeletal complaints the possibility of Lyme disease should be evaluated. The decrease of antibody titers may indicate a positive prognosis in patients with musculoskeletal manifestations of Lyme disease. Disclosure of Interests None declared
POS1395 NEUROFILAMENT LIGHT CHAIN, AN EARLY BIOMARKER FOR POLYNEUROPATHY IN HEREDITARY ATTR AMYLOIDOSIS.
Authors: A. F. Brunger, M. Berends, J. Bijzet, P. Van der Zwaag, B. J. Kroesen, C. Teunissen, S. In ‘t Veld, G. Drost, F. Lange, R. Gans, B. Hazenberg, H. L. A. Nienhuis
Journal: Annals of the Rheumatic Diseases (2022)

Background Serum neurofilament light chain (sNfL) is a sensitive marker for polyneuropathy (PNP) in hereditary transthyretin-related (ATTRv) amyloidosis patients and correlates with the severity of polyneuropathy [1-4]. We hypothesized that sNfL may diagnose neuronal damage in patients with hATTR amyloidosis before the onset of symptoms and before PNP can be detected by electromyography (EMG) examination. Objectives To establish the course of sNfL in three different groups: 1. persistently asymptomatic variant carriers (with and without detected amyloid), 2. ATTRv amyloidosis patients with PNP on treatment, 3. variant carriers who develop PNP. Methods sNfL levels were assessed longitudinally in asymptomatic variant carriers (with and without detectable amyloid), ATTRv amyloidosis patients with PNP on treatment (either a transthyretin (TTR) stabilizer or patisiran, an RNA interference therapeutic), and variant carriers who developed PNP. PNP was established by EMG examination. The single-molecule array (Simoa) assay was used to assess sNfL levels. Results sNfL levels significantly increased over 1 year in 20 persistently asymptomatic carriers (p&lt;0.001), with the strongest increase in variant carriers (n=8) with detectable amyloid in the subcutaneous abdominal fat tissue. In 21 symptomatic ATTRv amyloidosis patient with PNP on treatment with a TTR stabilizer, sNfL levels remained stable over 1 year. In 24 patients treated with patisiran, sNfL levels significantly decreased after 1 year of treatment (p=0.01). In 8 out of 9 variant carriers who developed PNP a rise in the sNfL level could be observed before the onset of symptoms and establishment of PNP by EMG examination (Figure 1). Figure 1. Conclusion sNfL is a marker for early neuronal damage since a rise in sNfL level occurs before abnormalities can be detected by EMG examination. Our data support the use of sNfL in monitoring disease progression, screening asymptomatic variant carriers and monitoring of treatment effect. References [1]Louwsma et al. Amyloid 2021;28(1):50-55 [2]Maia et al. Amyloid 2020;27(2):97-102 [3]Kapoor et al. J Perpher nerv syst 2019;24:314-319 [4]Ticau et al. Neurology 2021;96:e412-e422 Disclosure of Interests Anne Floor Brunger: None declared, Milou Berends: None declared, Johan Bijzet: None declared, Paul van der Zwaag: None declared, Bart-Jan Kroesen: None declared, Charlotte Teunissen: None declared, Sjors in ‘t Veld: None declared, Gea Drost: None declared, Fiete Lange: None declared, Reinold Gans: None declared, Bouke Hazenberg Consultant of: Alnylam and Pfizer, Hans L.A. Nienhuis Consultant of: Alnylam and Pfizer
AB1466 CORRELATION BETWEEN SALES OF CERTAIN BEVERAGES AND GOUT ATTACKS DURING THE COVID-19 CURFEW IN CAMEROON: A HOSPITAL-BASED STUDY
Authors: F. Kemta Lekpa, K. Frank Forex, H. Mbatchou, A. Jerome, H. Namme Luma, S. P. Choukem
Journal: Annals of the Rheumatic Diseases (2022)

Background An unusual increase in the number of gout cases was observed in Cameroon in 2020. Was there a link with lifestyle changes during confinement, especially the consumption of certain types of beverages (beer, liquor, water, sweetened drinks)? Objectives To determine if there was a correlation with the consumption of different beverages (water, beer, liquor, sweetened drinks). Methods Cross-sectional study in the rheumatology consultation of the Douala General Hospital, from January 1 to December 31, 2020, including all patients with a diagnosis of gout (ACR/EULAR criteria of 2015). Pearson’s correlation (r) was used to determine the effect of the consumption of the different beverages on the increase in the number of gout cases. A p&lt;0.05 was significant. Results We included 1952 patients, including 111 gout cases (107 men; median age: 51 years [36-81]). Compared with the same period in 2018 and 2019, a peak in gout cases was observed between May and November 2020 (Figure 1). In the same period, a positive correlation existed between the number of gout cases and the increase in sales of liquor (r=0.8434, p=0.034) and sweetened beverages (r=0.8436, p=0.034). This correlation was not significant for beer sales (r=0.7980, p=0.057) [Table 1]. Table 1. Correlation between the number of gout cases and sales of different types of drinks Variables Correlation coefficient (r ) p Beer 0.7980 0.0571 Liquor 0.8434 0.0349* Sweetened beverages 0.8436 0.0348* Water -0.7569 0.0815 Figure 1. Evolution of Gout cases from 2018 to 2020 The COVID-19 PCR test was negative in all patients. Conclusion The real “outbreak” of gout observed during the curfew related to COVID-19 between May and November 2020 was favored by a punctual increase in the consumption of liquors and sweetened drinks. Disclosure of Interests None declared
Evaluation of a Wastewater-Based Epidemiological Approach to Estimate the Prevalence of SARS-CoV-2 Infections and the Detection of Viral Variants in Disparate Oregon Communities at City and Neighborhood Scales
Authors: Blythe A. Layton, Devrim Kaya, Christine Kelly, Kenneth J. Williamson, Dana Alegre, Silke M. Bachhuber, Peter G. Banwarth, Jeffrey W. Bethel, Katherine Carter, Benjamin D. Dalziel, Mark Dasenko, Matthew Geniza, Andrea George, Anne-Marie Girard, Roy Haggerty, Kathryn A. Higley, Denise M. Hynes, Jane Lubchenco, Katherine R. McLaughlin, F. Javier Nieto, Aslan Noakes, Matthew Peterson, Adriana D. Piemonti, Justin L. Sanders, Brett M. Tyler, Tyler S. Radniecki
Journal: Environmental Health Perspectives (2022)

Positive correlations have been reported between wastewater SARS-CoV-2 concentrations and a community's burden of infection, disease or both. However, previous studies mostly compared wastewater to clinical case counts or nonrepresentative convenience samples, limiting their quantitative potential.
POS1061 HYPOVITAMINOSIS D IN PSORIATIC ARTHRITIS PATIENTS: PREDICTIVE ROLE ON DRUG SURVIVAL OF METHOTREXATE MONOTHERAPY AND FIRST LINE OF b-DMARDs.
Authors: C. Rotondo, D. Cici, S. Stefania, A. Altomare, F. P. Cantatore, A. Corrado
Journal: Annals of the Rheumatic Diseases (2022)

Background The immunomodulatory role of vitamin D is extensively studied enough to hypothesize a pathogenetic role in chronic arthritis and psoriasis. Few data has been published on possible interference of hypovitaminosis D on drug response in rheumatoid arthritis patients, but data in psoriatic arthritis (PsA) patients is completely lacking. Objectives To compare drug survival and retention rate of methotrexate (MTX) and the first line of biotechnological drugs (b-DMARDs) in PsA patients with hypovitaminosis D and those with normal level of vitamin D. Methods We conducted a retrospective study on 250 PsA patients (age 57,3 years ± 13,2). All patients were required to fulfill the CASPAR criteria for PsA and were tested for vitamin D levels at baseline visit. Clinical characteristics, MTX and first line of b-DMARDs treatment duration and comorbidities information were recorded for each patient. The evaluations of drug survivals were realized by Kaplan-Meier estimate, followed by log-rank (Mentel-Cox) test for the comparison between the groups of patients in study. Statistical significance was set at p ⩽ 0.05. Results Sixty-four percent of PsA patients presented hypovitaminosis D (22,2ng/ml ± 8,8). PsA patients with hypovitaminosis D and those with normal levels were comparable for age (56,8 years ± 13 vs 58,5 years ± 12), and disease activity at baseline visit (DAS 28 VES: 4 ± 0,8 vs 3,8 ± 0,8). MTX monotherapy survival was shorter in hypovitaminosis D group (90 ± 19 weeks vs 166,8 ± 28 weeks, p=0,041), with discontinuation risk hazard ratio = 1,4 (95% CI: 1,005 – 2,014; p=0,046). The drug survival of first line of b-DMARDs was significantly shorter in patients with hypovitaminosis D (246,1 ± 40 weeks vs 302,1 ± 35 weeks; p=0,048), with discontinuation risk hazard ratio = 1,5 (95% CI: 1,1-2,4; p=0,05). Conclusion Vitamin D seems play an important role not only in the regulation of immune system but also in the modulation on immune response induced by drugs, as MTX or b-DMARDs. The evaluation of sera levels of vitamin D at the begging of immunomodulatory therapy could have a predictive role on treatment management in PsA patients. Further studies should be useful to detect if supplementation of vitamin D could improve the performance of immunomodulatory drugs. Disclosure of Interests None declared
AB1011 FACTORS RELATED TO GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRAGILITY FRACTURES IN YOUNG SUBJECTS.
Authors: H. Florez, J. L. Carrasco, M. Barberá, J. Hernández-Rodríguez, A. Muxi, S. Prieto-González, M. C. Cid, A. Monegal, N. Guañabens, P. Peris
Journal: Annals of the Rheumatic Diseases (2022)

Background Glucocorticoid (GC) treatment is the most frequent cause of osteoporosis (OP) in young subjects. However, the factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF), and consequently, the therapeutic approach to GIOP in young populations is not well established. Objectives Analyze the prevalence of GIOP and FF in GC-treated patients and compare the risk factors related to their development according to age (&lt; and ≥50 years). Methods 127 patients (62±18 years) receiving chronic GC treatment were included (≥5 mg/day of prednisone, &gt;3 months). The clinical data collected included: dose and duration of GC treatment, disease activity, previous FF, anthropometric data, bone metabolism parameters (including bone turnover markers and the presence of hypogonadism), bone mineral density (by DXA; defining densitometric OP: T-score ≤-2.5 or Z-score ≤-2, depending on the age of the patient), trabecular bone score (by DXA), and vertebral fractures (X-ray). GIOP was defined as densitometric OP and/or FF. Results were compared between subjects &lt; and ≥50 years old. Results The prevalence of GIOP was similar in both age groups: &lt;50 (n=36) 44.4% vs. 46.1% ≥50 years (n=91). Five subjects &lt;50 (13.8%) and 30 ≥50 years (33%) presented FF (p=0.05). Young subjects with FF tended to be &gt;40 years, have a higher body mass index (BMI) (25.4 vs. 23.3, p=n.s.), and inflammatory disease activity (CRP 0.90 vs. 0.06mg/dL, p=0.06). When analyzing the differential risk factors related to FF depending on age, a higher body mass index (BMI) (29.63 vs. 26.95, p=0.048) and inflammatory disease activity (PCR -0.87 vs. -2.51 [log scale], p=0.03) were observed in young subjects, while low lumbar T-scores (-1.08 vs. -0.06 DE, p=0.003) and higher cumulative GC-doses (9.11 vs. 8.56 g, p=0.03) were differential factors in subjects over 50. Hypogonadism was a risk factor independent of age (OR 4.89; 95%CI 1.36-17.59), being associated with the presence of FF in both age groups. Conclusion More than 40% of the patients receiving GC developed GIOP, with a similar prevalence in both age groups (&lt; and ≥50 years); however, FF are less common in young subjects. Hypogonadism is a determining risk factor for FF independent of age. In addition, young subjects with FF tend to be older, with a higher BMI and disease activity, and, thus, evaluation of these risk factors can improve the identification of subjects at increased risk of fracture. Disclosure of Interests None declared
AB1231 ULTRASOUND-GUIDED INJECTION OF LOW MOLECULAR WEIGHT HYALURONIC ACID VERSUS STEROID FOR INFLAMMATORY AND DEGENERATIVE SACROILIITIS: A RANDOMIZED CONTROLLED TRIAL
Authors: K. Hosny, M. I. Abdelkareem, A. Moshrif
Journal: Annals of the Rheumatic Diseases (2022)

Background Sacroiliitis may be degenerative (DSI) or inflammatory (ISI) and the latter is one of the clinical features of spondyloarthropathies. Objectives To determine the effect of hyaluronic acid versus corticosteroid injection for chronic sacroiliac joint arthropathy. Methods forty patients with sacroiliitis either degenerative (DSI: 20 patients) or inflammatory (ISI: 20 patients) based on the New York criteria. Each group was allocated into 2 subgroups; 10 patients received 2ml Betamethasone dipropionate plus 2 ml lidocaine 2% (A) and 10 patients received 2 ml hyaluronic acid plus 2 ml lidocaine 2% (B). All sacroiliac joint injections were done under ultrasonographic guidance using a 22-gauge needle. Visual analogue scale was used for pain assessment at base line, 1, 2 and 4 week post injection. Results there was no significant difference between main groups (ISI &amp; DSI) regarding VAS score before injection, 1, 2 and 4 weeks after injection while there was a significant difference between subgroups A&amp;B in ISI group at 2 and 4 weeks (P= 0.012 and 0.008 respectively). Also, there was a significant difference between subgroups A &amp; B in DSI group at 1, 2 and 4 weeks after injection (P= 0.04, 0.006, and 0.005 respectively). There was a high significant difference before and after injection in the main groups and all subgroups. However, there was no significant difference between the subgroups of ISI and DSI. Conclusion both steroid and hyaluronic acid were effective in relieving pain in treatment of inflammatory and degenerative sacroiliitis but steroid was more efficacious than the hyaluronic acid. Disclosure of Interests Khalid Hosny: None declared, Mohamed Ismail Abdelkareem Speakers bureau: Abbvie, Jansen, Novartis and Organon, Abdelhfeez Moshrif Speakers bureau: Amgen, Jansen and Novartis